Histrelin Pregnancy and Breastfeeding Warnings

Brand names: Supprelin LA, Vantas

Medically reviewed by Drugs.com. Last updated on Aug 6, 2025.

Histrelin Pregnancy Warnings

Use is contraindicated.

US FDA pregnancy category: Not assigned

Risk summary: Animal studies have revealed evidence of increase in fetal loss at clinically relevant doses. Inadequate data available on the use of this drug in pregnant women to inform a drug-related risk.

Comments:
-This drug can harm a developing fetus.
-Adequate methods of contraception should be encouraged.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Animal studies have revealed evidence of embryotoxicity and teratogenicity (e.g., spontaneous abortions, major fetal abnormalities, increased fetal mortality, decreased fetal weights, reduced fertility). There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Histrelin Breastfeeding Warnings

This drug is not indicated for use in female patients.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-This drug can harm a nursing infant.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer